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Abstract
The emerging outbreak of the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2) continues to spread worldwide. We prescribed some promising medication to our patients with 
mild to moderate pneumonia due to SARS-CoV-2, however such drugs as chloroquine, hydrossichloroquine, azithromycin, 
antivirals (lopinavir/ritonavir, darunavir/cobicistat) and immunomodulating agents (steroids, tocilizumab) were not con-
firmed as effective against SARS-CoV2. We, therefore, started to use auto-hemotherapy treated with an oxygen/ozone  (O2/
O3) gaseous mixture as adjuvant therapy. In Udine University Hospital (Italy) we performed a case–control study involving 
hospitalized adult patients with confirmed COVID-19 with mild to moderate pneumonia. Clinical presentations are based 
upon clinical phenotypes identified by the Italian Society of Emergency and Urgency Medicine (SIMEU—Società Italiana di 
Medicina di Emergenza-Urgenza) and patients that met criteria of phenotypes 2 to 4 were treated with best available therapy 
(BAT), with or without  O3-autohemotherapy. 60 patients were enrolled in the study: 30 patients treated with BAT and  O2/O3 
mixture, as adjuvant therapy and 30 controls treated with BAT only. In the group treated with  O3-autohemotherapy plus BAT, 
patients were younger but with more severe clinical phenotypes. A decrease of SIMEU clinical phenotypes was observed 
(2.70 ± 0.67 vs. 2.35 ± 0.88, p = 0.002) in all patients during hospitalization but this clinical improvement was statistically 
significant only in  O3-treated patients (2.87 ± 0.78 vs. 2.27 ± 0.83, p < 0.001), differently to the control group (2.53 ± 0.51 vs. 
2.43 ± 0.93, p = 0.522). No adverse events were observed associated with the application of  O2/O3 gaseous mixture.  O2/O3 
therapy as adjuvant therapy could be useful in mild to moderate pneumonia due to SARS-CoV-2. Randomized prospective 
study is ongoing [Clinical Trials.gov ID: Z7C2CA5837].
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Introduction
The emerging outbreak of the coronavirus disease 2019 
(COVID-19) caused by the severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) continues to spread 
worldwide. According to the COVID-19 situation report 
published by the World Health Organization (WHO), a total 
of 14.3483858 confirmed cases and 603.691 deaths have 
been identified globally up to July 20th 2020 [1].
The full spectrum of COVID-19 ranges from mild, self-
limiting respiratory tract illness to severe progressive pneu-
monia, multi-organ failure, and death [2].
There is a reasonable hypothesis that after a first viral 
phase with low severity illness, there could be a host immune 
response with variable lymphopenia, and an inflammatory 
cytokines release syndrome (CRS) which would play an 
important role in severe COVID-19 cases, leading to wors-
ening acute respiratory failure [3].
In this context of CRS, patients could take advantage of 
 O3 gas anti-inflammatory and immune-modulatory proper-
ties. On this basis, we performed a case–control study in 
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patients with COVID-19 to assess  O3-autohemotherapy as 
adjuvant therapy, in addition to the prescription of standard 
treatments used such as hydrossi-chloroquine, azithromy-
cin, antivirals (lopinavir/ritonavir, darunavir/cobicistat) and 
immunomodulating agents (steroids, tocilizumab) [4, 5].
O2/O3 mixture, a gas discovered in the mid-nineteenth 
century, is a molecule consisting of three atoms of oxygen 
in a dynamically unstable structure due to the presence of 
mesomeric states [6].
Although  O3 gas has dangerous effects when inhaled, 
some reports on  O3 therapeutic effects have been 
documented.
Since the First World War, blood ozonization has shown 
an effective bacterial effect. Furthermore, the diffusion 
of several studies regarding patient infected by Ebola and 
treated with  O3 therapy demonstrate its capacity to stimulate 
oxygen metabolism and to modulate the immune system. 
During the First World War (1914–1918), doctors familiar 
with  O3 antibacterial properties, and with few other medical 
resources available, applied it topically to infected wounds, 
thus revealing  O3 hemodynamic and anti-inflammatory 
properties [6–8].
O3 therapy administration depends on treatment goals 
and location of therapy: it has been administered intrave-
nously, intramuscular, into body cavities (rectum, bladder, 
and vagina), joints, subcutaneous and soft tissues, intraperi-
toneally, and even intrathecally [9]. However, the first and 
most popular application is  O3 autohemotherapy  (O3-AHT) 
which requires a predetermined blood sample (100–200 mL) 
to be drown and thus, using stoichiometric calculations, a 
precise concentration of  O2-O3 can be infused. This small 
amount of blood is subjected to  O2-O3 ex-vivo and is then 
administered to the patients [10].
O3 has many further demonstrated mechanisms of action:
(1) Increase of red blood cell 2,3 di-glycerophosphate 
(greater hemoglobin oxygen release);
(2) Modulation of endothelial nitric oxide production;
(3) Induction of a greater arterial/venous partial pressure 
difference, indicating greater mitochondrial consump-
tion of oxygen (energy production);
(4) Modulation of the immune system and reduction of 
inflammation,
(5) Improvement of antioxidant status, antioxidant enzymes 
(including superoxide dismutase), and glutathione in 
cells [9];
In vitro  O3 interferes with virus-to-cell contact in lipid-
enveloped viruses via oxidation of lipoproteins, proteins, and 
glycoproteins, thus interfering with the viral reproductive 
cycles [10].
O3 in the blood reacts with plasma antioxidant and gives 
rise to several messengers, among them  H2O2, that readily 
diffuses into immune cells. Moreover,  O3 acts as a regulator 
in signal transduction, facilitating several immune responses 
[11, 12].
Another important effect of  O3-AHT in the COVID-19 
therapeutical context is the down-regulation action of pyrin 
domain-containing protein 3 (NLRP3) inflammasome, 
which is known to play a crucial part in the initiation and 
continuance of inflammation in various diseases [13].
The rationale of blood ozonization is to evaluate the addi-
tive anti-inflammatory and immunomodulatory action medi-
ated by  O3 in patients hospitalized for SARS-CoV-2.
Methods
Study patients
Male and non-pregnant female patients 18 years of age or 
older were eligible if they had a diagnostic specimen that 
was positive to RT-PCR for SARS-CoV2 and pneumonia 
confirmed by chest imaging. All patients gave their informed 
consent to participate in the study. Exclusion criteria were 
pregnancy, G6PHD (glucose 6 phosphate dehydrogenase) 
deficiency, concomitant serious diseases and failure to 
obtain informed consent.
This study was approved by the Friuli Venezia Giulia eth-
ics committee (Protocol n° Z7C2CA5837).
The full spectrum of COVID-19 ranges from mild, self-
limiting respiratory tract illness to severe progressive pneu-
monia, multi-organ failure, and death. The Italian Society of 
Emergency and Urgency Medicine (SIMEU—Società Itali-
ana di Medicina di Emergenza-Urgenza) suggests to classify 
the COVID-19 patients in 5 clinical phenotypes [14]:
• Phenotype 1: subjects with fever and without respira-
tory failure (normal Arterial Blood Gas analysis—ABG-, 
six-minute walking test—6mWT—and Chest XR). These 
patients can usually manage at home maintaining a quar-
antine period.
• Phenotype 2: subjects with fever but with ABG and/or 
Chest XR indicative of modest respiratory insufficiency 
(PO2 > 60 mmHg in ambient air) and/or pulmonary con-
solidation area. These patients need to be hospitalized 
because they can worsen quickly.
• Phenotype 3: subjects with fever associated with 
moderate-severe respiratory insufficiency (at triage 
PO2 < 60 mmHg in ambient air) and/or bilateral pulmo-
nary consolidation area at Chest XR. These patients need 
to be treated with high flow oxygen therapy.
• Phenotype 4: subjects with respiratory failure with sus-
pected ARDS (Adult Respiratory Distress Syndrome) or 
complicated pneumonia. These patients require hospitali-
zation in a sub-intensive care unit.
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• Phenotype 5: subjects suffering from ARDS initially. 
These patients will require Intensive Care Unit (ICU) 
admission and non-invasive positive pressure ventilation 
(NIPPV) or mechanical ventilation.
In the present study, we enrolled subjects with modest to 
moderate respiratory insufficiency (SIMEU clinical pheno-
types 2–4) hospitalized in an infectious disease ward.
For all patients were recorded age, gender, presence of 
obesity, Charlson comorbidity index, delta time from symp-
toms onset to hospital admission, hospital length of stay, 
and symptoms (fever, dry cough, dyspnea, syncope, myalgia, 
asthenia, diarrhea, hypo/dysgeusia, hypo/anosmia).
The other best available therapy (BAT) administered 
included: antiretroviral therapy (lopinavir/ritonavir 2 tablets 
every 12 h, darunavir/cobicistat 1 tablet per day), hidrossy-
cloroquine 400 mg every 12 h than the first day, followed by 
200 mg every 12 h for other 4 days, tocilizumab iv 10 mg/kg 
in single dose, amiodarone, azithromycin, other antibiotics 
and steroids.
The endpoints of the study were: SIMEU clinical phe-
notypes at admission and discharge, delta classes SIMEU 
(negative values mean clinical improvements), admission 
to Intensive Care Unit (ICU) and death. Blood gas analysis 
(BGA) parameters were recorded at admission. Further-
more, baseline value of White Blood Cells (WBC), lym-
phocytes count, platelets, CPK, LDH and IL-6 blood level 
were reported.
Medical ozone  (O3) procedure
The systemic  O3 treatment procedure was decided by the 
physician on duty and started first at the patient’s bedside 
with the drawing of autologous blood and, after proper  O2/
O3 mixing, with its re-infusion. After inserting a catheter 
in the patient’s vein which was connected to a latex-free 
plastic bag, containing 35 ml of sodium citrate, a blood 
amount of 200 ml was drown from the patient. At the end, 
the withdrawal line was washed and re-used to infuse saline 
solution. The blood, without any patient disconnection, was 
then mixed with a gas mixture of a 200 ml composed by 
96%  O2 and 4%  O3, with a  O3 therapeutic range of 40 μg/
mL of gas per mL blood. To guarantee the  O2/O3 homogene-
ous diffusion into the blood, the bag was gently mixed for 
about 10 min, subsequently, the blood was re-infused into 
the patient.  O3 treatment lasted for 3 consecutive days.
Outcome
The end-point was the time of respiratory improvement and 
earlier weaning from oxygen support: these parameters were 
included in the SIMEU clinical phenotypes classification.
Statistical analyses
All variables were reported as mean ± standard deviation, 
median and interquartile interval or proportion, depending 
on their distribution. Accordingly, comparisons between 
treated and controls were performed with independent sam-
ples two-tailed t test, Mann–Whitney test or chi-squared test 
with continuity correction. Mixed ANOVA was used to com-
pare the SIMEU class values, cross-classified by treatment 
and time (before and after treatment). Paired sample’s t test 
was used when appropriate. For analyses, the R statistical 
software was used [15].
Results
A total of 60 patients were enrolled in the study: 30 with 
 O3-AHT as adjuvant therapy added to BAT and 30 con-
trols treated with BAT only. Among the 30 patients treated 
with  O3-AHT (cases group), 28 received three consecutive 
 O3-AHT sections, and 2 received two consecutive doses.
Table 1 shows the baseline demographic and clinical 
characteristics of the 60 patients enrolled in the study. The 
control group treated with BAT only were older and with 
more co-morbidities than the other group. Instead, patients 
treated with  O3-AHT as adjuvant therapy had a more seri-
ous clinical respiratory condition with lower  PaO2/FiO2 and 
 SpO2/FiO2 ratio and lower lymphocytes count.
Notably, SIMEU clinical phenotypes at hospital admis-
sion were slightly higher in  O3-treated patients, meaning that 
their conditions were more severe, even if the difference was 
not fully statistically significant (2.87 ± 0.78 vs. 2.53 ± 0.51, 
p = 0.054).
In general, a decrease of SIMEU clinical phenotypes was 
observed (2.70 ± 0.67 vs. 2.35 ± 0.88, p = 0.002) in overall 
population during hospitalization. However, this clinical 
improvement was statistically significant only in  O3-treated 
patients (2.87 ± 0.78 vs. 2.27 ± 0.83, p < 0.001) and not in 
the control group (2.53 ± 0.51 vs. 2.43 ± 0.93, p = 0.522).
Figure 1 shows the clinical improvement (in green) in 
the two groups, in  O3 group there was a 53% improvement 
with respect to 33% of the control group. In the group with 
 O3-AHT adjuvant therapy, only 7% of patients had a worse 
outcome, compared with 17% in the control group.
Figure 2 shows all the 30 patients treated with  O3-AHT 
adjuvant therapy, according to the improvement of SIMEU 
clinical phenotypes and the time of  O3-AHT therapy; 26 out 
of 30 patients were treated in the first 5 days after hospital 
admission. Four patients (two for each group) were intu-
bated, and only two patients died in the control group.
Given the nature of this preliminary study, data on a 
limited number of laboratory measures were collected. No 
adverse events were recorded in both patients’ arms.
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Discussion
This preliminary report describes the clinical outcomes 
in a small group of patients with COVID-19 who were 
moderately ill (SIMEU clinical phenotypes 2–4) and were 
treated with BAT plus  O3-AHT with respect to BAT alone. 
Specifically, clinical improvement status was observed in 
53% of the patients in the  O3 group and 33% in the control 
group; instead, the clinical stability was observed in 40% of 
 O3-AHT group and in 50% in the control group, failure was 
Table 1  Comparison of clinical characteristics of patients treated with blood ozonization vs. controls
BGA blood gasses analysis, CK creatine, FiO2 fraction of inspired oxygen, ICU intensive care unit, IL-6 interleukin-6 (normal range: < 7 pg/ml), 
IOT tracheal intubation, LDH lactate dehydrogenase, PaO2 arterial oxygen tension, WBC white bloods cells, time from symptoms onset to hospi-








Male 41 (68%) 23 (77%) 18 (60%) 0.267
Age (years) 61 ± 13 57 ± 12 65 ± 13 0.0148
Charlson Comorbidity Index 2 [1–3] 1 [0–3] 2 [1–4] 0.0445
Obesity 7 (12%) 3 (10%) 4 (13%) 1
Δ time symptoms—hospital admissions (days) 7 [5–9] 7 [5–8] 7 [5–9] 0.9345
Hospital stay (days) 9.37 ± 4.63 9.37 ± 3.84 9.37 ± 5.38 1
Fever 58 (97%) 30 (100%) 28 (93%) 0.472
Cough 33 (55%) 21 (70%) 12 (40%) 0.0379
Dyspnoea 30 (50%) 17 (57%) 13 (43%) 0.4386
Syncope 3 (5%) 1 (3%) 2 (7%) 1
Myalgia 7 (12%) 4 (13%) 3 (10%) 1
Asthenia 32 (53%) 20 (67%) 12 (40%) 0.0701
Diarrhoea 13 (22%) 6 (20%) 7 (23%) 1
Hypo/dysgeusia 22 (37%) 13 (43%) 9 (30%) 0.4216
Hypo/anosmia 18 (30%) 9 (30%) 9 (30%) 1
Antiretroviral therapy 59 (98%) 30 (100%) 29 (97%) 1
Tocilizumab therapy 21 (35%) 12 (40%) 9 (30%) 0.5883
Amiodarone 2 (3%) 1 (3%) 1 (3%) 1
Azithromycin 20 (33%) 11 (37%) 9 (30%) 0.7842
Other antibiotics 19 (32%) 12 (40%) 7 (23%) 0.267
Systemic steroids 2 (3%) 1 (3%) 1 (3%) 1
Clinical SIMEU Class—Admission 2.7 ± 0.67 2.87 ± 0.78 2.53 ± 0.51 0.0545
Clinical SIMEU Class—Discharge 2.35 ± 0.88 2.27 ± 0.83 2.43 ± 0.94 0.4678
Δ Clinical SIMEU Class 0 [− 1–0] − 1 [− 1–0] 0 [− 1–0] 0.0436
Clinical worsening 7(12%) 2 (7%) 5 (17%) 0.4212
ICU admission for IOT 4 (7%) 2 (7%) 2 (7%) 1
Death 2 (3%) 0 (0%) 2 (7%) 0.472
BGA—Admission
 PaO2 (mmHg) 74.1 ± 19.9 71.8 ± 17.0 76.4 ± 22.5 0.3681
 FiO2 (%) 25.7 ± 8.6 27.6 ± 9.3 23.7 ± 7.6 0.0753
 PaO2/FiO2 ratio 307 ± 101 277 ± 87 336 ± 107 0.0234
 O2 Saturation 96.4 ± 2.6 96.4 ± 2.3 96.4 ± 2.8 0.9601
 SpO2/FiO2 ratio 403 ± 87 377 ± 93 429 ± 75 0.0202
WBC (/mmc) 5.61 ± 2.57 5.57 ± 2.43 5.65 ± 2.75 0.9049
Lymphocytes (/mmc) 0.91 ± 0.3 0.83 ± 0.3 0.98 ± 0.3 0.0497
Platelets (/mmc) 196.8 ± 82.3 213.5 ± 102.6 180.1 ± 51.7 0.1187
LDH (U/L) 616 ± 253 675 ± 278 558 ± 213 0.0711
C reactive protein (mg/L) 75.7 [38.1–118.8] 76.4 [45.5–122.3] 67.6 [26.2–107.7] 0.3711
CK (U/L) 100 [64–193] 105 [71–201] 93 [61–155] 0.5242
IL-6 (pg/ml) 36.5 [20.0–68.3] 44.[21–58] 33.0 [20.0–78.0] 0.7947
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observed in 7% of  O3-AHT group with respect to 17% of the 
control group. Mortality was observed in only two cases in 
the control group: the low rate of mortality may be due to the 
patients’ profiles enrolled in the study with mild or moderate 
cases of pneumonia due to SARS-CoV-2.
Case fatality Rate (CFR) in Friuli Venezia Giulia was 
0.3% at July 20th 2020 while in Italy CFR was 14.3% [16], 
however, mortality was very different across the regions 
and wards of admission [17–19]. This mortality rate in 
our patients with mild to moderate pneumonia was not 
surprising.
None of the patients enrolled in the study were intubated 
at the moment of the inclusion, whereas at the end four 
patients were intubated, 2 for each group. In a recent study of 
compassionate use of remdesivir [20], 64% of patients were 
intubated at the baseline and mortality was 18%, instead in 
less severe cases, mortality was 5%, very similar to the value 
observed in our study.
Fig. 1  Comparison of clinical 
classes in subjects treated with 
blood ozonation compared to 
controls
Fig. 2  Change in clinical classes 
before and after blood ozoniza-
tion during the hospital stay
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To note that, respect to the World Health Organization 
guidance [21], that is based on clinical data and radio-
logical data only for patients with ARDS and designed 
for clinicians caring COVID-19 patients during all phases 
of their disease (i.e. screening to discharge), the SIMEU 
clinical phenotypes [14] use both clinical and radiological 
criteria for all patients, allowing a better patients stratifica-
tion during the first phase of the disease, especially in the 
field of emergency medicine and might be more precise in 
patients stratification during the follow-up. This classifica-
tion might be more useful for evaluating the clinical and 
radiological improvement of patients included in a clinical 
trial on COVID-19.
Although several limitations, the present study suggests 
that the clinical effectiveness of  O2/O3 therapy in addition 
to the standard of care ensured at Udine University Hospital 
in patients with mild to moderate COVID-19 pneumonia. 
The  O3-AHT therapy is based on oxidative preconditioning 
[22] that leads to the reduction of IL-6 and IL-1b [23]. This 
effect can explain a cytoprotective action observed during 
 O3-AHT therapy. Furthermore,  O3-AHT therapy has been 
used in viral infection (Ebola, Influenza and HIV) with pre-
liminary good results [10, 24].
Unfortunately, our study did not collect viral load data to 
confirm the anti-viral effects of  O2/O3 therapy.
No adverse events were detected during  O3-AHT therapy, 
neither haemolysis or local vein damages.
Interpretation of the results of this study is limited 
because of the small size of the enrolled group, the short 
duration of follow-up, the potential missing data due to 
the retrospective nature of this study, and the lack of a 
randomization.
Although the latter precludes definitive conclusions, com-
parisons with contemporaneous cohorts from the literature 
suggest that  O2/O3 therapy may have a clinical benefit in 
patients with mild to moderate COVID-19 pneumonia.
Physicians desperately need therapy for COVID-19. Pub-
lished case reports might support inexpensive  O2/O3 utility 
for infectious disease management, not only for microbicidal 
activity but also for the immunomodulation activity.  O3 (and 
other oxidation) therapy carries virtually no known adverse 
or toxic effects when performed properly (other than spo-
radic vein issues, as can other intravenous therapies).
Me (C.T.) has never administered  O3-AHT therapy before 
COVID-19, and the discussion with the anaesthesiologist 
(A.D.M.) brought us to try a therapy with few adverse effects 
for an infection without any available therapy.  O2/O3 is not 
the panacea for all diseases, however, evidence-based medi-
cine strongly suggests that randomized prospective studies 
are necessary. On this basis, according to the ethical com-
mittee of Region Friuli Venezia Giulia, Italy, we started a 
multicentre prospective randomized study of therapy with 
BAT with or without  O3-AHT adjuvant therapy for mild to 
moderate pneumonia due to COVID-19. The study is cur-
rently ongoing [Clinical Trials.gov ID: Z7C2CA5837].
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